A Double-Blind Randomised 2-Arm, 2-Period Crossover Study to Access the Similarity of Safety and Pharmacokinetics of JHL1922 and Pulmozyme® After Single and Repeated Administration in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 25 Jul 2018
At a glance
- Drugs Dornase alfa (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors JHL Biotech
- 01 Mar 2018 According to a JHL Biotech media release, the Dutch Healthcare Authority has approved the Clinical Trial Application (CTA) for JHL1922 facilitating initiation of this trial in Netherlands in March 2018.
- 22 Feb 2018 Status changed from planning to recruiting, as reported in a JHL Biotech media release.
- 26 Dec 2017 New trial record